Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.

Bowen DJ, Collins PW, Lester W, Cumming AM, Keeney S, Grundy P, Enayat SM, Bolton-Maggs PH, Keeling DM, Khair K, Tait RC, Wilde JT, Pasi KJ, Hill FG; UK Haemophilia Centre Doctors' Organization.

Br J Haematol. 2005 Mar;128(6):830-6.

PMID:
15755288
2.

C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.

Keeney S, Grundy P, Collins PW, Bowen DJ.

Haemophilia. 2007 Jul;13(4):405-8.

PMID:
17610557
3.
4.

C1584: effect on von Willebrand factor proteolysis and von Willebrand factor antigen levels.

Davies JA, Collins PW, Hathaway LS, Bowen DJ.

Acta Haematol. 2009;121(2-3):98-101. doi: 10.1159/000214848. Epub 2009 Jun 8. Review.

PMID:
19506354
5.

Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.

Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, van Mourik JA.

Thromb Haemost. 2008 May;99(5):916-24. doi: 10.1160/TH07-09-0565.

PMID:
18449422
6.

Insights into von Willebrand factor proteolysis: clinical implications.

Bowen DJ, Collins PW.

Br J Haematol. 2006 Jun;133(5):457-67. Review.

PMID:
16681634
7.

An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P; UK Haemophilia Centre Doctors' Organisation.

Thromb Haemost. 2006 Nov;96(5):630-41.

PMID:
17080221
8.

Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.

Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, Obert B, Ribba AS, Girma JP.

J Thromb Haemost. 2007 Feb;5(2):321-8. Epub 2006 Nov 1.

9.
10.
11.

Type 1 von Willebrand disease: a possible novel mechanism.

Bowen D.

Blood Coagul Fibrinolysis. 2004 May;15 Suppl 1:S21-3.

PMID:
15166929
12.

Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.

Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S, Schneppenheim R.

Blood. 2006 Mar 15;107(6):2339-45. Epub 2005 Dec 1.

13.

Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. Review.

PMID:
16959681
14.

A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.

O'Brien LA, Sutherland JJ, Hegadorn C, Benford K, Racz H, Rapson D, Hough C, Lillicrap D.

J Thromb Haemost. 2004 Jul;2(7):1135-42.

17.

The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.

Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting PJ, Rapson D, Lillicrap D, James P.

J Thromb Haemost. 2008 Jan;6(1):90-6. Epub 2007 Oct 8.

18.
19.

Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.

Mannucci PM, Capoferri C, Canciani MT.

Br J Haematol. 2004 Jul;126(2):213-8.

PMID:
15238142
20.

Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study.

James PD, Paterson AD, Notley C, Cameron C, Hegadorn C, Tinlin S, Brown C, O'Brien L, Leggo J, Lillicrap D; ASSOCIATION OF HEMOPHILIA CLINIC DIRECTORS OF CANADA.

J Thromb Haemost. 2006 Apr;4(4):783-92.

Supplemental Content

Support Center